Literature DB >> 23359778

The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer.

Jun Liu1, Xiang Liu, Fei Cui, Guoqin Chen, Yubao Guan, Jianxing He.   

Abstract

OBJECTIVE: To observe the efficacy of the inhalation of an aerosolized group A streptococcal (GAS) preparation in treating orthotopic lung cancer in mouse models and assess the feasibility, safety, and effectiveness of this administration mode for lung cancer.
METHODS: Lewis lung carcinoma (LLC) cell strains were administered via intrathoracic injection to establish orthotopic lung cancer mouse models. After the tumor-bearing models were successfully established, as confirmed by computed tomography, the mice were administered by inhalation with an aerosolized GAS preparation (GAS group) or aerosolized normal saline (control group). The anti-tumor effect of the aerosolized GAS preparation was evaluated histologically; meanwhile, the survival and quality of life were compared between these two groups.
RESULTS: The aerosolized GAS preparation showed remarkably anti-tumor effect, causing the necrosis of the orthotopic lung cancer cells in tumor-bearing mice. Furthermore, mice in the GAS group had significantly better quality of life and longer survival than those in control group.
CONCLUSIONS: The inhalation of aerosolized GAS preparation may be a feasible, safe and effective solution for lung cancer.

Entities:  

Keywords:  Group A streptococcal (GAS); Lewis lung carcinoma cell; lung cancer

Year:  2012        PMID: 23359778      PMCID: PMC3551315          DOI: 10.3978/j.issn.1000-9604.2012.10.08

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  20 in total

Review 1.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

2.  The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer.

Authors:  Pei-Jye Voon; Byoung Chul Cho; Wee-Lee Yeo; Ross A Soo
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

3.  The value of delayed (18)F FDG-PET imaging in diagnosis of solitary pulmonary nodules: A preliminary study on 28 patients.

Authors:  Peng Yang; Xiao-Yang Xu; Xiao-Jing Liu; Jing-Shan Gong
Journal:  Quant Imaging Med Surg       Date:  2011-12

4.  Active-specific immunotherapy for non-small cell lung cancer.

Authors:  Hauke Winter; Natasja K van den Engel; Margareta Rusan; Nina Schupp; Christian H Poehlein; Hong-Ming Hu; Rudolf A Hatz; Walter J Urba; Karl-Walter Jauch; Bernard A Fox; Dominik Rüttinger
Journal:  J Thorac Dis       Date:  2011-06       Impact factor: 2.895

5.  Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung.

Authors:  Bart P H Wittgen; Peter W A Kunst; Kasper van der Born; Atie W van Wijk; Walter Perkins; Frank G Pilkiewicz; Roman Perez-Soler; Susan Nicholson; Godefridus J Peters; Pieter E Postmus
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

Review 6.  Cetuximab in non-small-cell lung cancer.

Authors:  Robert Pirker; Martin Filipits
Journal:  Transl Lung Cancer Res       Date:  2012-03

7.  Chemotherapy of lung cancer: A global perspective of the role of ifosfamide.

Authors:  Caicun Zhou; Christian Manegold
Journal:  Transl Lung Cancer Res       Date:  2012-03

8.  Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy.

Authors:  T Misaki; Y Watanabe; Y Iida; A Hidaka; K Kasagi; H Fukushima; J Konishi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432.

Authors:  K Oshimi; S Kano; F Takaku; K Okumura
Journal:  J Natl Cancer Inst       Date:  1980-12       Impact factor: 13.506

10.  SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis.

Authors:  Seong-Hoon Park; Yuming Zhu; Ozkan Ozden; Hyun-Seok Kim; Haiyan Jiang; Chu-Xia Deng; David Gius; Athanassios Vassilopoulos
Journal:  Transl Cancer Res       Date:  2012-05-22       Impact factor: 1.241

View more
  3 in total

1.  Expression and significance of miRNA-21 and BTG2 in lung cancer.

Authors:  Qing Sun; Meng Hang; Xuedan Guo; Wenlong Shao; Guangqiao Zeng
Journal:  Tumour Biol       Date:  2013-07-16

2.  Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer.

Authors:  Zhi-Hua Liu; Fu-Fu Zheng; Yu-Ling Mao; Lie-Fu Ye; Jun Bian; De-Hui Lai; Yun-Lin Ye; Yu-Ping Dai
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

3.  MicroRNA‑21 regulates the expression of BTG2 in HepG2 liver cancer cells.

Authors:  Bijing Mao; He Xiao; Zhimin Zhang; Dong Wang; Ge Wang
Journal:  Mol Med Rep       Date:  2015-07-07       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.